Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy: “Otsuka—people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated to clinical development of promising drug candidates in mental health, oncology, cardio-renal, and nephrology. Other activities include strategic planning for drug approval, marketing, and lifecycle management to maximize a product’s full potential.
OPDC is an indirect subsidiary of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately USD 11 billion in 2016.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en.
Otsuka Pharmaceutical Company
2440 Research Blvd.
Rockville, MD 20850
609-524-6788
www.otsuka-us.com
Blog: www.otsuka-us.com/discover/only-otsuka-blog
Twitter: @OtsukaUS
LinkedIn: @OtsukaUS
Leadership:
Dr. William H. Carson, President & CEO OPDC
Dr. Margaretta Nyilas, Sr. Vice President Clinical Management & Business Operations
Dr. Raymond Sanchez, Sr. Vice President Global Clinical Development
New Business Contact:
Sang Le, Sr. Director, Head of Global Alliance Management & Business Development
sang.le@otsuka-us.com
What Makes Us Innovative:
Otsuka is focused on digital innovation to lead the research and development of pharmaceuticals in a new direction. Through ODH, Inc. we have invested in providing innovative data analytics solutions to transform healthcare. At Otsuka Pharmaceutical Development & Commercialization, Inc. we have embraced a paperless and digitized ePlatform model across all clinical studies, which has allowed us to exceed expectations by locking a database in less than 24 hours. Otsuka has also pushed boundaries with the early development of a digital medicine, a key building block of the future: ABILIFY MYCITE®, the first digital medicine approved by FDA, is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an ingestible event sensor.
